{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:19:57Z","timestamp":1760908797687,"version":"3.37.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T00:00:00Z","timestamp":1366243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005627","name":"Thrasher Research Fund","doi-asserted-by":"publisher","award":["02826-2"],"award-info":[{"award-number":["02826-2"]}],"id":[{"id":"10.13039\/100005627","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spastic Paralysis Research Foundation"},{"name":"Chicago Institute of Neurosurgery and Neuroresearch"},{"name":"Ronald McDonald House Charities of Central Illinois"},{"DOI":"10.13039\/100007087","name":"Questcor Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007087","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,18]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Opsoclonus\u2013myoclonus syndrome (OMS) is a neuroinflammatory disorder associated with remote cancer. To understand more clearly the role of inflammatory mediators, the concentration of CXCR3 ligands CXCL10, CXCL9 and CXCL11 was measured in 245 children with OMS and 81 paediatric controls using enzyme-linked immunosorbent assay (ELISA), and CXCR3 expression on CD4+ T cells was measured by flow cytometry. Mean cerebrospinal fluid (CSF) CXCL10 was 2\u00b77-fold higher in untreated OMS than controls. Intrathecal production was demonstrated by significantly different CXCL10 CSF\u2009:\u2009serum ratios. The dichotomized \u2018high\u2019 CSF CXCL10 group had higher CSF leucocyte count (P\u2009=\u20090\u00b70007) and B cell activating factor (BAFF) and CXCL13 concentrations (P\u2009&amp;lt;\u20090\u00b70001). CSF CXCL10 did not correlate with clinical severity or relapse using grouped data, although it did in some patients. Among seven types of immunotherapy, including rituximab or chemotherapy, only adrenocorticotrophic hormone (ACTH) monotherapy showed reduced CSF CXCL10, but prospective longitudinal studies of ACTH combination therapies indicated no reduction in CXCL10 despite clinical improvement (P\u2009&amp;lt;\u20090\u00b70001). CXCL10 concentrations were 11-fold higher in CSF and twofold higher in serum by multiplexed fluorescent bead-based immunoassay than enzyme-linked immunosorbent assay, but the two correlated (r\u2009=\u20090\u00b77 and 0\u00b783). In serum, no group differences for CXCL9 or CXCL11 were found. CXCR3 expression on CD4+ T cells was fivefold higher in those from CSF than blood, but was not increased in OMS or altered by conventional immunotherapy. These data suggest alternative roles for CXCL10 in OMS. Over-expression of CXCL10 was not reduced by clinical immunotherapies as a whole, indicating the need for better therapeutic approaches.<\/jats:p>","DOI":"10.1111\/cei.12065","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T08:26:46Z","timestamp":1358411206000},"page":"427-436","source":"Crossref","is-referenced-by-count":16,"title":["Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus\u2013myoclonus syndrome"],"prefix":"10.1093","volume":"172","author":[{"given":"M R","family":"Pranzatelli","sequence":"first","affiliation":[{"name":"Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E D","family":"Tate","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N R","family":"McGee","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Travelstead","sequence":"additional","affiliation":[{"name":"Flow Cytometry Facility"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Verhulst","sequence":"additional","affiliation":[{"name":"Department of Statistics and Research Consulting, Southern Illinois University School of Medicine, Springfield, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R M","family":"Ransohoff","sequence":"additional","affiliation":[{"name":"The Lerner Research Institute, Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,4,18]]},"reference":[{"key":"2021122009535927700_cei12065-bib-0001","first-page":"217","article-title":"The biology of chemokines and their receptors","volume":"18","author":"Rossi","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2021122009535927700_cei12065-bib-0002","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","article-title":"CXCL10 and autoimmune diseases","volume":"8","author":"Lee","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2021122009535927700_cei12065-bib-0003","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2990.2010.01089.x","article-title":"Review: the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity\u2009\u2013\u2009a tale of conflict and conundrum","volume":"36","author":"M\u00fcller","year":"2010","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2021122009535927700_cei12065-bib-0004","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2990.2001.00312.x","article-title":"CXCR3 expression in human central nervous system diseases","volume":"27","author":"Goldberg","year":"2001","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2021122009535927700_cei12065-bib-0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/jcb.20052","article-title":"Regulation of neuroinflammation: the role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis","volume":"92","author":"Klein","year":"2004","journal-title":"J Cell Biochem"},{"key":"2021122009535927700_cei12065-bib-0006","first-page":"95","article-title":"Chemokines and chemokine receptors: their manifold roles in homeostasis and disease","volume":"1","author":"Le","year":"2004","journal-title":"Cell Mol Immunol"},{"key":"2021122009535927700_cei12065-bib-0007","first-page":"152","article-title":"Opsoclonus\u2013myoclonus syndrome","volume-title":"Clinics in developmental medicine, no. 184\u2013185, inflammatory and autoimmune disorders of the nervous system in children","author":"Pranzatelli","year":"2010"},{"key":"2021122009535927700_cei12065-bib-0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105\u2009U.S. cases of pediatric opsoclonus\u2013myoclonus","volume":"22","author":"Tate","year":"2005","journal-title":"J Pediatr Oncol Nurs"},{"key":"2021122009535927700_cei12065-bib-0009","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus\u2013myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"2021122009535927700_cei12065-bib-0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.12.014","article-title":"Key role of CXCL13\/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS","volume":"243","author":"Pranzatelli","year":"2012","journal-title":"J Neuroimmunol"},{"key":"2021122009535927700_cei12065-bib-0011","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cyto.2008.06.001","article-title":"Therapeutic down-regulation of central and peripheral B-cell activating factor (BAFF) production in opsoclonus\u2013myoclonus","volume":"44","author":"Pranzatelli","year":"2008","journal-title":"Cytokine"},{"key":"2021122009535927700_cei12065-bib-0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2011.02.012","article-title":"Cerebrospinal fluid oligoclonal bands in childhood opsoclonus\u2013myoclonus","volume":"45","author":"Pranzatelli","year":"2011","journal-title":"Pediatr Neurol"},{"issue":"Suppl. 11","key":"2021122009535927700_cei12065-bib-0013","first-page":"S112","article-title":"Interferon-inducible protein 10 (CXCL10) is increased in the cerebrospinal fluid of children with opsoclonus\u2013myoclonus syndrome","volume":"62","author":"Pranzatelli","year":"2007","journal-title":"Ann Neurol"},{"key":"2021122009535927700_cei12065-bib-0014","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"2021122009535927700_cei12065-bib-0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1046-2023(02)00355-9","article-title":"Chemokine receptor expression on cerebrospinal fluid leukocytes","volume":"29","author":"Kivis\u00e4kk","year":"2003","journal-title":"Methods"},{"key":"2021122009535927700_cei12065-bib-0016","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2990.2000.026002133.x","article-title":"Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions","volume":"26","author":"Simpson","year":"2000","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2021122009535927700_cei12065-bib-0017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jns.2006.05.049","article-title":"Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis","volume":"247","author":"Franciotta","year":"2006","journal-title":"J Neurol Sci"},{"key":"2021122009535927700_cei12065-bib-0018","first-page":"498","article-title":"Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis","volume":"72","author":"Mahad","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122009535927700_cei12065-bib-0019","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0404.2006.00629.x","article-title":"Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis","volume":"114","author":"Moreira","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"2021122009535927700_cei12065-bib-0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0165-5728(01)00261-2","article-title":"Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies","volume":"115","author":"Franciotta","year":"2001","journal-title":"J Neuroimmunol"},{"key":"2021122009535927700_cei12065-bib-0021","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1210\/jc.2004-1062","article-title":"Elevated serum interferon-gamma-inducible chemokine-10\/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines","volume":"90","author":"Rotondi","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122009535927700_cei12065-bib-0022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000081856","article-title":"Expression of TH1\/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis","volume":"52","author":"Nakajima","year":"2004","journal-title":"Eur Neurol"},{"key":"2021122009535927700_cei12065-bib-0023","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1172\/JCI5150","article-title":"Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients","volume":"103","author":"S\u00f8rensen","year":"1999","journal-title":"J Clin Invest"},{"key":"2021122009535927700_cei12065-bib-0024","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cyto.2005.08.004","article-title":"Elevated interleukin-12 and CXCL10 in subacute sclerosing panencephalitis","volume":"32","author":"Saruhan-Direskeneli","year":"2005","journal-title":"Cytokine"},{"key":"2021122009535927700_cei12065-bib-0025","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/art.20598","article-title":"Interferon-inducible protein 10\/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus","volume":"50","author":"Okamoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021122009535927700_cei12065-bib-0026","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/bjo.2003.040980","article-title":"Optic neuritis: chemokine receptor CXCR3 and its ligands","volume":"88","author":"S\u00f8rensen","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"2021122009535927700_cei12065-bib-0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jneuroim.2005.03.005","article-title":"Increased expression of CXCR3 and CCR5 on memory CD4+ T-cells migrating into the cerebrospinal fluid of patients with neuroborreliosis: the role of CXCL10 and CXCL11","volume":"163","author":"Lepej","year":"2005","journal-title":"J Neuroimmunol"},{"key":"2021122009535927700_cei12065-bib-0028","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archneur.63.4.538","article-title":"Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease","volume":"63","author":"Galimberti","year":"2006","journal-title":"Arch Neurol"},{"key":"2021122009535927700_cei12065-bib-0029","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/269541","article-title":"The imbalance in serum concentration of Th-1- and Th-2-derived chemokines as one of the factors involved in pathogenesis of atopic dermatitis","volume":"2009","author":"Narbutt","year":"2009","journal-title":"Mediators Inflamm"},{"key":"2021122009535927700_cei12065-bib-0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cyto.b.20021","article-title":"Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers","volume":"61","author":"Khan","year":"2004","journal-title":"Cytometry B Clin Cytom"},{"key":"2021122009535927700_cei12065-bib-0031","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainresrev.2004.07.021","article-title":"Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases","volume":"48","author":"Cartier","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"2021122009535927700_cei12065-bib-0032","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1568008053174723","article-title":"CXCR3-binding chemokines: novel multifunctional therapeutic targets","volume":"5","author":"Lazzeri","year":"2005","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"2021122009535927700_cei12065-bib-0033","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2567.2010.03384.x","article-title":"Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes","volume":"132","author":"Korniejewska","year":"2011","journal-title":"Immunology"},{"key":"2021122009535927700_cei12065-bib-0034","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1073\/pnas.96.12.6873","article-title":"CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions","volume":"96","author":"Balashov","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122009535927700_cei12065-bib-0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1468-1331.2003.00638.x","article-title":"Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables","volume":"10","author":"Putheti","year":"2003","journal-title":"Eur J Neurol"},{"key":"2021122009535927700_cei12065-bib-0036","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0165-5728(02)00263-1","article-title":"Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing\u2013remitting multiple sclerosis","volume":"131","author":"Sindern","year":"2002","journal-title":"J Neuroimmunol"},{"key":"2021122009535927700_cei12065-bib-0037","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1164\/ajrccm.164.5.2008132","article-title":"Effects of oral steroids on blood CXCR3+ and CCR4+ T cells in patients with bronchial asthma","volume":"164","author":"Kurashima","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2021122009535927700_cei12065-bib-0038","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1468-1331.2001.00327.x","article-title":"Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis","volume":"8","author":"S\u00f8rensen","year":"2001","journal-title":"Eur J Neurol"},{"key":"2021122009535927700_cei12065-bib-0039","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2172-13-2","article-title":"A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection","volume":"13","author":"Jenh","year":"2012","journal-title":"BMC Immunol"},{"key":"2021122009535927700_cei12065-bib-0040","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/ar2823","article-title":"Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis","volume":"11","author":"Nanki","year":"2009","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12065","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/172\/3\/427\/41788142\/cei12065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/172\/3\/427\/41788142\/cei12065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:26:28Z","timestamp":1641054388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/172\/3\/427\/6421032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,4,18]]},"published-print":{"date-parts":[[2013,4,18]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12065","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"type":"electronic","value":"1365-2249"},{"type":"print","value":"0009-9104"}],"subject":[],"published-other":{"date-parts":[[2013,6]]},"published":{"date-parts":[[2013,4,18]]}}}